Diagonal Bio

The pilot test is set to provide faster and more accurate, point-of-care diagnostics, potentially leading to quick action to increase the well-being of StallZet’s trot training facility. StallZet manages over 190 horses and has a vast national and international network in the trotter and racehorse segment.

The collaboration with StallZet provides Diagonal Bio AB with a unique opportunity to expand the reach of its diagnostic platform, LAMPlify®. The renowned trainer and leader Daniel Redén at StallZet has long experience in trotting. Additionally, Daniel Redén and StallZet’s vast network of professionals—including veterinarians, trainers, and specialists—will not only offer key connections but also valuable insights, aiding in the broader international adoption of the platform within the equestrian sector.

The collaboration and pilot test with StallZet allow Diagonal Bio to strengthen its partnerships within this sector. It involves cooperation in both the horse training environment and the veterinary field, with a focus on supporting equestrian events. This initiative opens up a new potential market while enhancing horse welfare, as early detection of respiratory infections is vital for maintaining healthy horses.

"At StallZet, we are always striving to give our horses the best possible care. Working with Diagonal Bio offers a unique opportunity to enhance horse welfare by quickly identifying health issues and ensuring top-quality care even before the break-out. I really see a huge opportunity for the entire horse industry including the different associations internationally start using LAMPlify® to identify sick horses before entering racetracks or arenas, and to be able to isolate them at their home stables in order not to infect others"- Daniel Redén, trainer at StallZet

"We are proud to partner with StallZet in this pilot. With their extensive experience and international network in horse competitions, StallZet is a valued partner to test our diagnostic platform. We believe our technology can make a significant impact, in horse welfare more broadly" - Karin Wehlin, CEO of Diagonal Bio AB (publ)

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 3, 2024, at 12:15 CET.

For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.